Light, metabolic syndrome and Alzheimer's disease: a non-pharmacological approach

光、代谢综合征和阿尔茨海默病:非药物方法

基本信息

项目摘要

Project Summary/Abstract This study's main hypothesis is that a delivering a tailored lighting intervention (TLI) will provide a successful means for promoting circadian entrainment and treating metabolic disease and inflammation in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) and Alzheimer's disease and related dementias (ADRD). As such, the proposed studies have the potential to provide important insights into the link between AD/ADRD and type 2 diabetes (T2DM) by identifying the disruption of circadian rhythms as a key component in the metabolic impairment. It would open new avenues of investigation, as it would raise the possibility that brain insulin resistance is indeed a consequence of disrupted circadian rhythm. Preliminary data from ongoing studies demonstrates a beneficial effect of light treatment on sleep and depression. If positive results are observed, the potential also exists to transform the manner in which homes, assisted living facilities, and nursing homes are lighted by delivering a simple, practical, non-pharmacological intervention to promote entrainment, improve sleep, and reduce metabolic disease in AD and mild AD MCI patients. The specific aims of the proposed research are two-fold. First, a randomized, placebo-controlled, crossover study involving 60 AD/ADRD patients who live in controlled environments (i.e., assisted living facilities and nursing homes), will investigate whether 8 weeks of exposure to a TLI designed to increase circadian entrainment (measured via urinary melatonin) improves sleep (actigraphy and questionnaires), mood (questionnaire), inflammatory markers, and metabolic control (oral glucose tolerance tests) compared to a control, circadian-inactive light. Second, using a single-arm, between-subjects design, placebo- controlled study we will investigate if long-term (6-month) exposure to TLI improves glucose homeostasis and insulin sensitivity in 30 patients with mild AD/ADRD and sleep disturbances, who will be recruited from the Mount Sinai AD research center (ADRC) and randomized to receive TLI (or dim light control treatment) at home. We will test if the TLI improves insulin sensitivity (SI) and glucose disposal (SG) as assessed through the frequently sampled IV glucose tolerance test (FSIVGTT) to dissect mechanisms through which circadian re-entrainment improves metabolism. The strengths of this project are considerable, especially given the unavailability of instruments for measuring personal circadian light exposure patterns. If successful, the study will open the way for a practical, effective non-pharmacological treatment for significantly reducing the two diseases' burden on society and, more directly, on caregivers. The unique, diverse research team is composed of experts in the fields of geriatric psychiatry, endocrinology, and light and circadian research, all of whom have direct access to the clinical population. This project is also highly translational, as the PIs will use the information gathered through this research to work with manufacturers in the development of lighting fixtures for this application.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPH BUETTNER其他文献

CHRISTOPH BUETTNER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPH BUETTNER', 18)}}的其他基金

Role of CREG1 in metabolic homeostasis
CREG1 在代谢稳态中的作用
  • 批准号:
    10608346
  • 财政年份:
    2023
  • 资助金额:
    $ 91.52万
  • 项目类别:
Light, metabolic syndrome and Alzheimer's disease: a non-pharmacological approach
光、代谢综合征和阿尔茨海默病:非药物方法
  • 批准号:
    10357437
  • 财政年份:
    2021
  • 资助金额:
    $ 91.52万
  • 项目类别:
Neural mechanisms for VGF regulation of energy balance
VGF 调节能量平衡的神经机制
  • 批准号:
    10197299
  • 财政年份:
    2018
  • 资助金额:
    $ 91.52万
  • 项目类别:
Light, metabolic syndrome and Alzheimer’s disease: a non-pharmacological approach
光、代谢综合征和阿尔茨海默病:非药物方法
  • 批准号:
    9927956
  • 财政年份:
    2018
  • 资助金额:
    $ 91.52万
  • 项目类别:
Neural mechanisms for VGF regulation of energy balance
VGF 调节能量平衡的神经机制
  • 批准号:
    9616382
  • 财政年份:
    2018
  • 资助金额:
    $ 91.52万
  • 项目类别:
Neural mechanisms for VGF regulation of energy balance
VGF 调节能量平衡的神经机制
  • 批准号:
    10208870
  • 财政年份:
    2018
  • 资助金额:
    $ 91.52万
  • 项目类别:
A Role of Hypothalamic Dysfunction in Alcoholic Liver Disease
下丘脑功能障碍在酒精性肝病中的作用
  • 批准号:
    9530801
  • 财政年份:
    2017
  • 资助金额:
    $ 91.52万
  • 项目类别:
A Role of Hypothalamic Dysfunction in Alcoholic Liver Disease
下丘脑功能障碍在酒精性肝病中的作用
  • 批准号:
    8859014
  • 财政年份:
    2014
  • 资助金额:
    $ 91.52万
  • 项目类别:
A Role of Hypothalamic Dysfunction in Alcoholic Liver Disease
下丘脑功能障碍在酒精性肝病中的作用
  • 批准号:
    8785952
  • 财政年份:
    2014
  • 资助金额:
    $ 91.52万
  • 项目类别:
PROTEOMIC STUDY OF HEPATIC METABOLISM REGULATED BY HYPOTHALAMIC PATHWAYS
下丘脑通路调控的肝脏代谢的蛋白质组学研究
  • 批准号:
    8365471
  • 财政年份:
    2011
  • 资助金额:
    $ 91.52万
  • 项目类别:

相似海外基金

Effects of dexmedetomidine on agitation in critically ill TBI patients - DEX-TBI
右美托咪定对危重 TBI 患者躁动的影响 - DEX-TBI
  • 批准号:
    488402
  • 财政年份:
    2023
  • 资助金额:
    $ 91.52万
  • 项目类别:
    Operating Grants
Relationship between Biomarkers of Oxidative Stress and Agitation Severity in Moderate-to-severe Alzheimer's Disease
中重度阿尔茨海默病氧化应激生物标志物与躁动严重程度之间的关系
  • 批准号:
    497994
  • 财政年份:
    2023
  • 资助金额:
    $ 91.52万
  • 项目类别:
Co-design and evaluation of sensor-instrumented ‘smart socks’ (MPATIX) to improve management of distress and agitation for people with dementia
共同设计和评估传感器仪表“智能袜子”(MPATIX),以改善痴呆症患者的痛苦和躁动管理
  • 批准号:
    10055596
  • 财政年份:
    2023
  • 资助金额:
    $ 91.52万
  • 项目类别:
    Collaborative R&D
Identifying pre-agitation biometric signature in dementia patients: A feasibility study
识别痴呆症患者的躁动前生物识别特征:可行性研究
  • 批准号:
    486612
  • 财政年份:
    2022
  • 资助金额:
    $ 91.52万
  • 项目类别:
    Studentship Programs
Relationship between 4-Hydroxynonenal and Agitation Severity in Alzheimer’s Disease
4-羟基壬烯醛与阿尔茨海默病患者躁动严重程度之间的关系
  • 批准号:
    486589
  • 财政年份:
    2022
  • 资助金额:
    $ 91.52万
  • 项目类别:
    Studentship Programs
Agitation in Alzheimer's Disease: Identification and Prediction Using Digital Behavioral Markers and Indoor Environmental Factors
阿尔茨海默病中的躁动:使用数字行为标记和室内环境因素进行识别和预测
  • 批准号:
    10404523
  • 财政年份:
    2021
  • 资助金额:
    $ 91.52万
  • 项目类别:
Clinical Decision Support Tool to Assess Risk and Prevent Agitation Events
用于评估风险和预防躁动事件的临床决策支持工具
  • 批准号:
    10683499
  • 财政年份:
    2021
  • 资助金额:
    $ 91.52万
  • 项目类别:
Development of Memesto, a wearable repetitive message and music therapy device that senses and reduces agitation in persons with AD/ADRD.
开发 Memesto,一种可穿戴式重复信息和音乐治疗设备,可感知并减少 AD/ADRD 患者的躁动。
  • 批准号:
    10322846
  • 财政年份:
    2021
  • 资助金额:
    $ 91.52万
  • 项目类别:
Agitation in Alzheimer's Disease: Identification and Prediction Using Digital Behavioral Markers and Indoor Environmental Factors
阿尔茨海默病中的躁动:使用数字行为标记和室内环境因素进行识别和预测
  • 批准号:
    10190522
  • 财政年份:
    2021
  • 资助金额:
    $ 91.52万
  • 项目类别:
Clinical Decision Support Tool to Assess Risk and Prevent Agitation Events
用于评估风险和预防躁动事件的临床决策支持工具
  • 批准号:
    10365272
  • 财政年份:
    2021
  • 资助金额:
    $ 91.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了